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Adeno-associated virus (AAV) is non-pathogenic and its various serotypes demonstrate a 
range of tissue tropism, making it an ideal vector candidate for targeted gene therapy. Although 
cardiac-specific AAVs have previously been identified, their specificity in targeting individual 
cell types within the heart is unknown. We sought to identify an AAV serotype that 
preferentially targets cardiac fibroblasts for the pointed delivery of cardiac reprogramming 
factors. We analyzed eight AAVs, including four newly engineered serotypes, for their cardiac 
cell-type targeting. Four were intravenously injected via the tail vein and four were directly 
injected into the heart chamber of three-month-old C57BL/6 mice. Each serotype was equipped 
with a GFP tag to serve as a reporter of virally transduced cells. Immunofluorescence co-staining 
for GFP and cell-type specific markers revealed targeting of cardiomyocytes only. We then 
characterized the differences in targeting efficiency and infection distribution in the heart tissue 
for the eight serotypes. Analysis indicated that GFP distribution varied significantly between 
intravenously administered AAVs, while directly injected AAVs showed strong GFP localization 
at the injection site. Next, we performed RNAscope in-situ hybridization to assess the mean 
RNA transcript copy number per cell and found serotype differences in RNA-level expression 
and protein-level expression of transduced genes. The data obtained from this study 
experimentally confirms the cell-type targeting specificity of cardiac AAVs in the heart. 
Serotype differences in infection efficiency, distribution, and transcript copy number will be 







Adeno-associated viruses (AAVs) are small, replication-defective, nonenveloped viruses 
that house a linear single-stranded DNA (ssDNA) genome that is approximately 4.7 kilobases 
(kb) long.1,2 The genome consists of two open reading frames (ORFs) encoding proteins required 
for viral replication and capsid formation flanked by inverted terminal repeats (ITRs) that are 
responsible for efficient encapsidation of viral DNA.3 AAVs are non-pathogenic and elicit little 
to no immunological response.4,5 As such, AAVs can be manipulated to generate recombinant 
AAVs (rAAVs) that are ideal vector candidates for targeted gene therapy. 
Recombinant AAVs are generated by substituting viral AAV genes with modified genes 
of interest that are then packaged by the ITRs and delivered safely to patient cells.1 Unlike most 
viral vectors, the removal of viral AAV replication genes causes the DNA to be packaged as 
circular concatemers that remain episomal instead of integrating into the host genome.6 
Furthermore, these episomes are gradually diluted with each round of replication, eliminating the 
possibility of a residual viral footprint on nuclear DNA.6,7  
Depending upon the protein composition of the capsid, AAV serotypes exhibit a broad 
range of tissue tropism that, when manipulated to form rAAVs, allows for targeted gene delivery 
and treatment of specific organs.2 For example, AAV1 is known to target the central nervous 
system and skeletal muscle, AAV2 is particularly efficient in targeting the kidneys, and AAV5 
has high transduction efficiency in the eye.8-13 Additionally, the route of administration acts as a 
secondary determinant of AAV tropism.14 To explore the capabilities of rAAVs, researchers 
have begun engineering novel serotypes with new and enhanced tropism by manipulating capsid 
composition and assembly.5,15-19  
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An estimated 121.5 million adults in the United States have heart disease, and ischemic 
heart disease (IHD) is the leading cause of mortality worldwide.20 Recombinant cardiac-specific 
AAVs have the potential to treat a number of cardiac pathologies by delivering therapeutic genes 
to affected heart tissue. In particular, AAV8 and AAV9 have shown high transduction efficiency 
in the heart.21-26 However, while organ specificity of many serotypes is well-understood, their 
capacity for targeting individual cell types within the heart is unknown. Understanding cell-type 
specificity is especially important because different cell types in the heart play distinct and 
separate roles in cardiac response to injury. For example, myocardial infarction (MI) results in 
the replacement of cardiomyocytes by scar tissue composed of cardiac fibroblasts. The formation 
of this non-conducting scar tissue on the heart muscle leads to a dramatic loss in contractility and 
pump function, increasing long-term risk of recurrent infarctions or heart failure (HF).20 
Here, we examined the cardiac cell-type specific targeting of four common AAV 
serotypes—AAV8, AAV9, AAV1, and RH10—and four newly engineered AAV serotypes—
CAM840, 158-scGFP, 1G, and 130G—in the adult murine heart. We sought to identify an AAV 
serotype that preferentially targets cardiac fibroblasts. Such a serotype would allow targeted 
delivery of cardiac reprogramming factors, which have previously been shown to 
transdifferentiate fibroblasts into functional cardiomyocytes both in vivo and in vitro.27,28 
Theoretically, the discovery and development of such a vector system could be harnessed for a 
safe and non-invasive treatment to repair the heart following MI.  
Methods: 
AAV Serotypes 
We investigated four commonly used AAV serotypes: AAV8, AAV9, AAV1, and RH10. 
Additionally, a collaborating laboratory developed four novel AAV serotypes—CAM840, 158-
5 
 
scGFP, 1G, and 130G—using traditional methods for generating capsid mutants and hybrid 
serotypes. All eight viruses were equipped with a self-complementing GFP tag. Such self-
complementing AAV approaches have shown more rapid onset of transgene expression, 
allowing a minimum of four weeks for the detection of AAV-GFP expression. 
Injections 
Intracardiac Injections 
Four AAV serotypes—AAV1, 158-scGFP, 1G, and 130G—were directly injected into 
the heart chamber of three-month old C57BL/6 mice that were bred in-house. Each mouse was 
injected with only one AAV serotype at a viral titer of 2.5 x 1010 copies in a total volume of 20 
μl, with a replicate injection in a second mouse. 
Intravenous Injections 
Four AAV serotypes—RH10, AAV9, CAM840, and AAV8—were intravenously 
injected into the tail vein of three-month old C57BL/6 mice that were bred in-house. Each mouse 
was injected with only one AAV serotype at a viral titer of 1 x 1011 copies in a total volume of 
200 μl. Replicate injections were performed for RH10 and AAV9, but not for CAM840 and 
AAV8 due to low viral yield.  
After intracardiac or intravenous injection, all mice were housed under standard 
conditions for a total of four weeks to allow the AAV serotypes to take effect. All experimental 
protocols were approved by the University of North Carolina Institutional Animal Care and Use 
Committee. 
Heart Perfusion and Cryosection Preparation 
Mice were euthanized using a CO2 chamber for 1-3 minutes. The mice were removed 
from the container and cervically dislocated before application of ethanol to the ventral side. The 
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skin was cut in a V-shape along the ribs. Then, the sternum was raised using tweezers and a cut 
was made immediately posterior to the breastbone to rupture the pericardial cavity and expose 
the heart. The aorta was cut and a pooling of blood was observed. A butterfly needle was 
injected into the apex and the heart was perfused slowly with 1-3 mL of KCl, 1-5 mL of PBS, 
and 5-7 mL of a sucrose and PFA solution. Once all the blood was flushed from the heart, it was 
cradled using tweezers and excised from the thoracic cavity. It was then placed in a petri dish 
filled with PBS and any excess tissue or solution were removed from the heart. The heart was 
transferred to a tube with 0.5% PFA and 5% sucrose/PBS and refrigerated overnight on a rocking 
surface. 
The hearts were briefly washed in a PBS + 5% sucrose solution at room temperature. 
Then, the hearts were placed in a PBS + 5% sucrose solution at room temperature for 15 minutes 
on a rocking surface. After 15 minutes, they were transferred to a fresh batch of PBS + 5% 
sucrose and rocked for 1 hour. Then, they were transferred to PBS + 10% sucrose and rocked for 
1 hour. After the hour, they were transferred to PBS + 20% sucrose and rocked for another hour. 
Finally, they were transferred to a PBS + 20% sucrose solution and rocked at 4℃ overnight. The 
hearts were then removed from the solution and cut into two equal halves along the transverse 
plane to observe the ventricles. The halves were placed into a mold which was introduced to ice-
cold isopentane to freeze the tissue. Upon freezing, the hearts were stored at -20℃ until they 
were sectioned and fixed to a glass microscope slide. 
Immunofluorescent Staining 
Cryosections were removed from -80℃ and allowed to thaw at room temperature for 15 
minutes. Using a PAP pen, a hydrophobic barrier was drawn around the sectioned tissue. The 
samples were then washed twice for 5 minutes each in a PBS-Tween solution. After the washes, 
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0.2% PBS-Triton was added to the samples for 15 minutes to permeabilize the tissue.  Following 
permeabilization, the tissue sections were blocked in a 5% BSA + PBS solution for 1 hour at 
room temperature. The primary antibody mix containing three antibodies—α-Actinin (1:200, 
from Sigma-Aldrich), GFP (1:500, from Abcam) and either Vimentin (1:500, from Abcam), 
CD31 (1:200, from BD), or Sma1 (1:200, from Sigma-Aldrich)—was then added to the tissue 
samples and they were stored at 4℃ overnight. 
The following day, sections were washed in PBS and incubated for 1 hour at room 
temperature with the following secondary antibodies: Alexa Fluor 488 (1:500, from Jackson 
Labs), Cy3 (1:500, from Jackson Labs), and Alexa Fluor 647 (1:500, from Jackson Labs). The 
samples were then washed three times in PBS and mounted with Vectashield Hardset Mounting 
Medium containing DAPI and stored at 4℃ for later visualization. 
RNAscope In-situ Hybridization  
All equipment and reagents were sourced from ACDbio as part of the RNAscope 
Fluorescent Multiplex Assay Kit. 
Pretreatment 
Thawed tissue sections were washed with 1X PBS and the slides were baked at 60℃ for 
30 minutes. To post-fix the samples, sections were immersed in prechilled 4% PFA at 4℃ for 15 
minutes. Sections were then dehydrated by sequential immersion in 50% EtOH, 70% EtOH, and 
100% EtOH for 5 minutes each at room temperature. A HybEZ oven was prewarmed to 40℃ for 
30 minutes while the tissue sections air dried. Dehydrated tissue sections were covered with 5-8 
drops of 5% hydrogen peroxide and incubated at room temperature for 10 minutes. The sections 
were then washed three times in distilled water and submerged in a bath of boiling (98-102℃) 
RNAscope 1X Target Retrieval Reagent for 15 minutes. Immediately afterwards, the slides 
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sections were transferred to a bath of distilled water and washed three times. The sections were 
then washed in fresh 100% EtOH and air dried at room temperature. A hydrophobic barrier was 
drawn around the sectioned tissue using a PAP pen, and 5 drops of RNAscope Protease III were 
added to each section. The sections were incubated in the HybEZ oven for 30 minutes at 40℃ 
and subsequently washed with distilled water three times.  
RNAscope Multiplex Fluorescent v2 Assay 
Excess liquid was removed from the slides and 6 drops of the double “Z” oligo probe 
designed to hybridize to target GFP-RNA was added to cover the tissue sections. The slides were 
incubated in the HybEZ oven for 2 hours at 40℃ and then washed with 1X Wash Buffer. Then, 
6 drops of each probe amplifier (AMP1, AMP2, AMP3) were sequentially added to the slides, 
with each amplifier being incubated in the oven for 30 minutes and washed with 1X wash buffer 
before the addition of the next amplifier. Next, 6 drops of HRP-C1 were added to the slides and 
incubated in the oven for 15 minutes. The slides were washed and 200 μL of Opal 690 
fluorophore was added and incubated in the oven for 30 minutes. The slides were washed, 6 
drops of HRP blocker were added, and the slides were incubated in the oven for 15 minutes. The 
slides were washed again and all excess liquid was removed. A WGA-Alexa Fluor 555 antibody 
(1:500, from Thermo Fisher Scientific) was added, the slides were incubated for an hour, and 
then washed with PBS. To counterstain the slides, 4 drops of DAPI were added and the slides 
were mounted with ProLong Gold Antifade Mountant (from Thermo Fisher Scientific). The 
samples were stored at 4℃ in the dark for later visualization.  
Fluorescence Microscopy 
Stained tissue sections were imaged using the EVOS M5000 Imaging System from 
Thermo Fisher Scientific. Individual images were captured for each fluorophore on a separate-
9 
 
colored channel and overlaid to construct a composite image. The images were then analyzed for 
overlapping signals between GFP and the respective cell-type specific markers, as well as 
overlapping signals between GFP and the RNAscope probe. 
Image Quantification 
Viral Efficiency 
A minimum of 20 images per viral serotype was used to calculate viral efficiency. The 
number of cardiomyocytes and GFP+ cardiomyocytes present in each image was manually 
counted using ImageJ software. Only cells that had definite boundaries were counted and the 
presence of endothelial cells was used to delineate the boundary between 2-4 cardiomyocytes. To 
ensure consistency, cardiomyocytes were counted first and a cell was only counted as GFP+ if it 
overlapped perfectly with a previously counted cardiomyocyte. The mean percentage of GFP+ 
cardiomyocytes was then calculated for each of the eight viral serotypes to determine their 
relative targeting efficiencies. Significance was determined using a t-test. 
Viral Distribution 
Distribution calculations were quantified using the images collected from slide scans of 
the whole heart sections for each virus. Slide scans were performed at the Translational 
Pathology Laboratory (TPL) of the University of North Carolina School of Medicine. The same 
camera and laser intensity were used for each slide. For samples where AAV serotypes were 
directly injected into the heart chamber, the site of injection was identified and denoted as point 
zero where there was no GFP intensity. Two 2.5 mm lines were then drawn branching out from 
point zero to measure GFP intensity in the heart using intensity along the left (negative) and the 
right (positive) of point zero as a model. For AAV serotypes that were intravenously injected, an 
arbitrary point in the left ventricle was established as point zero for each heart and two 2.5 mm 
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lines were drawn from that point. An intensity plot that measured GFP expression along these 
two lines was then created using the ImageJ software. 
Significant differences in distance from the arbitrary zero point were not calculated 
because intravenously injected hearts had GFP distribution throughout the heart. However, there 
were observable differences in GFP distribution from the injection site in hearts that were 
directly injected with an AAV serotype. As such, significant differences in the distance of GFP 
expression from the site of injection were calculated for these hearts, based on an arbitrary GFP 
intensity threshold of 35. The last point along the left and the right axes (distance in mm) in 
which GFP intensity crossed this threshold was recorded for each serotype. The difference in 
distance recorded from these points was then used to calculate significant differences in the 
distance of AAV-GFP distribution from the point of injection using a t-test.  
Results: 
Previous studies have shown that the route of AAV administration can serve as a 
secondary determinant of AAV tropism.14 As such, we administered four AAV serotypes 
(AAV8, AAV9, RH10, and CAM) via intravenous injection through the tail vein and four AAV 
serotypes (158-scGFP, 1G, 130G, and AAV1) via intracardiac injection into the heart chamber of 
adult three-month old C57BL/6 mice. Each serotype was equipped with a self-complementing 
GFP tag for detection of successful AAV infection. Although AAV expression should be evident 
within days after injection, a steady level of expression is not achieved for three to four weeks 
post-injection.29,30 To accurately estimate transduction, the mice were housed under standard 
conditions for four weeks until a stable GFP expression level was detectable. After four weeks, 
the mice were euthanized and their hearts were harvested for cryosectioning and 





Figure 1: Methods Overview and Timeline 
The serotypes RH10, AAV9, CAM840, and AAV8 were injected intravenously through the tail vein at a 
viral titer of 1 x 1011. The serotypes AAV1, 158-scGFP, 1G, and 130G were injected directly into the heart 
chamber at a viral titer of 2.5 x 1010. 
 
Each cryosection was stained with an antibody for GFP and the cardiomyocyte-specific 
marker α-actinin. In addition, each cryosection was stained with an antibody for one of three 
major cell types in the heart: fibroblasts, endothelial cells, and smooth muscle cells.  
Vimentin, a type III intermediate filament protein, was used as a marker for cardiac 
fibroblasts.31 Fluorescence imaging revealed that none of the intravenously injected AAV 
serotypes transduced cardiac fibroblasts, as demonstrated by lack of co-staining between GFP 
and vimentin (Fig. 2A3-D3). Similarly, none of the directly injected AAV serotypes displayed 
overlapping GFP and vimentin staining (Fig. 2E3-H3). However, GFP expression overlapped 
with the expression of the cardiomyocyte marker α-actinin for all eight serotypes independent of 




Figure 2: The tested AAV serotypes do not target cardiac fibroblasts. 
(A-D) None of the intravenously injected AAVs demonstrated co-staining of GFP (green) and vimentin 
(white). (E-H) None of the directly injected AAVs demonstrated co-staining of GFP and vimentin. Scale 
bars are 200 μm. 
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Next, we assessed the ability of the AAV serotypes to infect endothelial cells using the 
cell adhesion protein CD31 as a marker.32 No overlapping expression between CD31 and GFP 
was observed, indicating a lack of endothelial cell targeting for both the intravenously injected 
serotypes and the directly injected serotypes (Fig. 3A3-H3). Similarly, we evaluated the ability 
of the AAV serotypes to infect cardiac smooth muscle cells using the marker smooth muscle 
actin 1 (SMA1).33 However, there was no overlapping expression of SMA1 and GFP which 
indicated a lack of smooth muscle cell targeting for all eight serotypes (Fig. 4A3-H3). 
Altogether, these results suggest that none of the commonly recognized cardiac-specific AAV 
serotypes nor the newly engineered serotypes tested here target cardiac fibroblasts, endothelial 
cells, or smooth muscle cells. Instead, all eight serotypes display preferential targeting of 
cardiomyocytes.  
Although the AAVs only demonstrated infection of cardiomyocytes, we noticed an 
empirical difference between the number of GFP+ cardiomyocytes transduced by each serotype. 
To better characterize the activity of each AAV serotype in the heart, we investigated the 
differences in cardiomyocyte transduction efficiency and distribution. Cryosections of each AAV 
infected heart were stained with equivalent amounts of GFP antibody on the same day and 










Figure 3: The tested AAV serotypes do not target cardiac endothelial cells. 
(A-D) None of the intravenously injected AAVs demonstrated co-staining of GFP (green) and CD31 
(white). (E-H) None of the directly injected AAVs demonstrated co-staining of GFP and CD31. Scale bars 





Figure 4: The tested AAV serotypes do not target cardiac smooth muscle cells. 
(A-D) None of the intravenously injected AAVs demonstrated co-staining of GFP (green) and SMA 
(white). (E-H) None of the directly injected AAVs demonstrated co-staining of GFP and SMA. Scale bars 




Intravenously injected AAVs demonstrated distributed GFP expression throughout the 
heart, indicating a remarkable ability of these viruses to disperse throughout the entire organ 
(Fig. 5A-D). However, there were notable differences in transduction efficiency between the four 
intravenously injected AAVs. RH10 demonstrated the highest transduction efficiency with a 
majority of the cells in the heart expressing GFP (Fig. 5A1-3, E). AAV9 also demonstrated high 
transduction, but the number of GFP+ cells was notably lower than the RH10 serotype (Fig. 
5B1-3, E). Both CAM and AAV8 demonstrated low transduction efficiency with small clusters 
of GFP+ cells throughout the heart (Fig. 5C1-3 and D1-3). Quantification of the average number 
of GFP+ cells revealed statistically significant differences between all four serotypes (Fig. 5F).  
We also observed differences in the intensity of the GFP+ cells throughout the tissue. 
Both RH10 and AAV9 demonstrated fairly consistent GFP intensity throughout the heart (Fig. 
5G, H). CAM displayed relatively low GFP intensity with occasional spikes of high intensity 
(Fig. 5I). AAV8 had consistently low GFP intensity across the limited number of infected cells 
(Fig. 5J). A map of the GFP expression frequency and intensity revealed that RH10 and AAV9 




Figure 5: Intravenously injected AAVs show GFP expression throughout the heart. 
(A1-D1) AAV-driven GFP expression is detected throughout the heart at different transduction 
efficiencies. Scale bar is 3 mm. (A2-D2) Zoomed in inset of areas with characteristic GFP expression. 
Scale bar is 0.5 mm. (A3-D3) Schematic depicting overall level of GFP transduction in section. (E) 
Transduction efficiencies of the intravenously injected serotypes. (F) Average number of GFP+ 
cardiomyocytes were significantly different for each viral comparison. (G-J) Distribution of GFP intensity 
observed from an arbitrary zero point in the left ventricle. (K) Overall comparison of GFP intensity. 
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In contrast to intravenously injected serotypes, the directly injected serotypes 
demonstrated highly localized GFP expression (Fig. 6A-D). There was considerably lower 
variation in the number of GFP+ cells in the directly injected hearts. AAV1 had the highest mean 
percentage of GFP+ cardiomyocytes which was significantly different from the lowest mean 
percentage of GFP+ cardiomyocytes exhibited by the 130G serotype (Fig. 6E, F). There was no 
significant difference in the mean percentage of GFP+ cardiomyocytes between AAV1 and 158-
scGFP or 1G. However, there was a significant difference between the 1G serotype and the 130G 
serotype (Fig. 6F).  
The most notable and variable feature of directly injected AAVs was GFP intensity and 
the degree to which each serotype patterned outwards from the injection site (Fig. 6A3-D3). For 
the AAV1 serotype, there was a high number of GFP+ cells with strong GFP intensity at the 
injection site, but this number quickly diminished within less than 1 mm from the site of 
injection (Fig. 6G). In contrast, the 1G serotype maintained a consistent level of GFP intensity 
for a distance of more than 2 mm from the injection site (Fig. 6I). There was a significant 
difference in the distance from the injection site where AAV1 and 1G dropped below an 
arbitrary GFP intensity threshold of 35 (Fig. 6K).  
Similarly, 158-scGFP displayed more variable GFP intensity that extended to at least 2 
mm away from the injection site (Fig. 6H), whereas 130G displayed variable high GFP intensity 
at the injection site but quickly dropped to background levels at a 1 mm distance (Fig. 6J). A 
large-scale comparison of intensity and distribution reveals a significant difference in the cellular 





Figure 6: Directly injected AAVs show localized GFP expression around the injection site.  
(A1-D1) AAV-driven GFP expression is mainly at the injection site with similar transduction efficiencies. 
Scale bar is 3 mm. (A2-D2) Zoomed in inset of areas with characteristic GFP expression. Scale bar is 0.5 
mm. (A3-D3) Schematic depicting overall level of GFP transduction. (E) Transduction efficiencies of the 
directly injected serotypes. (F) Average number of GFP+ cardiomyocytes were significantly different 
between AAV1 and 130G; 1G and 130G. (G-J) Distribution of GFP intensity observed from the injection 
site. (K) Overall comparison of GFP intensity. 
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To evaluate the reasons for variable GFP intensity and the various infection patterns 
observed for the different serotypes, we performed RNAscope in-situ hybridization that was 
capable of capturing RNA transcript levels at single molecule resolutions. We observed that 
intravenously injected AAVs showed comparatively lower levels of RNA transcripts per cell and 
GFP+ cardiomyocytes were rarely observed coinciding with the RNA transcripts (Fig. 7A4-D4). 
In contrast, directly injected AAVs showed comparatively higher levels of RNA transcripts per 
cell and the GFP+ cardiomyocytes showed strong co-staining with cells containing high levels of 
RNA transcripts (Fig. 7E4-H4).  
For the intravenously injected AAVs, CAM showed the highest number of RNA 
transcripts despite showing the lowest number of GFP+ cells. There was no significant difference 
observed between the number of RNA transcripts in cells for the intravenously injected AAVs 
(Fig. 7I). For the directly injected AAVs, 1G showed the highest number of RNA transcripts 
followed by 130G, AAV1, and 158-scGFP respectively. There was a significant difference 
between the mean RNA transcripts per cell for AAV1 and 158sc-GFP, along with 130G and 158-
scGFP (Fig. 7J). These data indicate that there are differences between the RNA-level expression 




Figure 7: Virally transduced genes show observable differences between RNA-level expression and 
protein-level expression. 
(A-D) Intravenously injected AAVs showed lower RNA transcript numbers in GFP+ cardiomyocytes. GFP+ 
cells were rarely observed coinciding with high levels of RNA transcripts. (E-H) Directly injected AAVs 
showed higher RNA transcript numbers in GFP+ cardiomyocytes. GFP+ cells showed strong co-staining 
with cells containing high levels of RNA transcripts. Scale bar is 50 μm. (I) RNA transcript number is 
highest for CAM 840 despite it showing the lowest number of GFP+ cells. (J) There is a significant 
difference in RNA transcript number between AAV1 and 158-scGFP; 130G and 158-scGFP.  
 
Discussion: 
To our knowledge, this is the first study to experimentally evaluate cell-type specific 
targeting of broadly described tissue-specific AAVs. Interestingly, all the cardiac-specific AAVs 
that were investigated demonstrated faithful targeting to only cardiomyocytes. No AAV serotype 
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that specifically targets cardiac fibroblasts was identified which is consistent with existing 
evidence within the field.  
Although not identified in this study, an AAV serotype capable of targeting cardiac 
fibroblasts may still exist. Since fibroblasts are a component of connective tissue, we speculate 
that AAV serotypes with a tropism for organs composed of a greater degree of connective tissue 
may be better candidates for targeting cardiac fibroblasts rather than cardiac-specific AAVs. A 
potential candidate could be AAV2 which has been documented to possess a remarkable tropism 
for human keratinocytes present in the skin with a molecular profile similar to fibroblasts.34 
Alternatively, it may be possible to engineer novel AAV capsids to generate new AAV serotypes 
with a propensity to infect fibroblasts.  
The results also illuminate the possibility that other tissue-specific AAV serotypes might, 
in fact, have specificity to only one cell-type within a targeted organ. This might explain the 
tendency for many AAV serotypes to demonstrate off-target specificity to other organs. What is 
interpreted as off-target specificity may instead be targeted affinity for a specific cell-type or 
associated cell-type with a shared molecular property. Altogether, this finding highlights the 
importance of thoroughly understanding the role of individual cell types in an organ and 
investigating AAV specificity at the cell-type specific level.  
This study also broadens the current understanding of several commonly used cardiac-
specific AAVs. For example, AAV8 and AAV9 are the most widely used cardiac-specific 
serotypes.21-26 However, AAV8 showed the lowest transduction efficiency in this study. 
Furthermore, while AAV9 had high transduction efficiency, the RH10 serotype significantly 
outperformed AAV9 and may be better suited for achieving high-yield cardiac targeting with 
limited viral titers. Previously, RH10 has not been used to target the murine heart but has been 
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shown to induce high transgene expression in the brain and spinal cord of murine neonates.35 
Therefore, we have uncovered a previously unknown target organ for a commonly used AAV 
serotype. Additionally, we have provided information on the targeting activity of four newly 
engineered cardiac-specific AAV serotypes. 
In addition to the targeting efficiency of cardiac-specific AAVs at the cell-type level, this 
study reveals key differences in AAV serotype transduction activity. In particular, the unusual 
trends and discrepancies observed between the mean RNA transcript copy number per cell and 
the detection of successfully translated GFP suggests that there are undiscovered cellular 
mechanisms that govern expression of virally transduced genes in eukaryotic cells. There may be 
regulatory mechanisms, including silencing microRNAs and temporally directed degradation of 
successfully translated mRNAs, that contribute to the observed mismatch between RNA-level 
expression and protein-level expression. 
Over the course of this study, we did not harvest any organs besides the heart for 
subsequent tissue analysis. Since the intravenously injected AAVs travel through the systemic 
circulation prior to infecting heart tissue, there is a possibility that they infected several other off-
target tissues and organs. As such, we gathered no data on the possibility of off-targets for the 
newly engineered AAV serotypes. Future studies with CAM840, 158-scGFP, 1G, and 130G 
might involve more extensive characterization of the tropism of the aforementioned serotypes by 
examining their localization across different organs following intravenous injection.  
The data presented in this study provides researchers with a resource for the selection of 
appropriate cardiac-specific AAVs for future research and therapeutic outcomes. It describes the 
transduction efficiency, distribution, and activity of cardiac-specific AAVs through intravenous 
and intracardiac injection. As such, researchers may choose the serotype and method of 
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administration that best reflects their desired level and pattern of transgene expression. 
Moreover, the presented data m ay prove useful for gene therapy efforts that involve 
delivery of modified genes to cardiomyocytes to generate a desired clinical outcome. 
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